Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) announce the availability of a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health.

Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types.

Bayer HealthCare officially opened its new life sciences hub for early stage research companies, dubbed the "CoLaborator™", in San Francisco's Mission Bay. The CoLaborator™-approach is to support start-ups in establishing their research labs, with academic researchers spinning out new firms.

Boehringer Ingelheim, the Institute of Molecular Health Science and the Institute of Food, Nutrition and Health of the ETH Zurich will collaborate to achieve new insights into the development of diabetes and obesity.

Abbott (NYSE: ABT) has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVaxTM), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.

Roche (SIX: RO, ROG; OTCQX: RHHBY) gave an update on its strategy, which continues to be focused on medical innovation and sustainable growth. Through its leadership in personalised healthcare, Roche is uniquely positioned to develop therapies that advance current standards of care and improve people's lives.

New data for Lucentis® (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.